Patent application EP19165966A (EP), filed 2019-03-28
Publication number: EP3715370A1
Title: HIGH AFFINITY ANTICALINS DIRECTED AGAINST HUMAN CD98HC
Abstract: The present invention relates to a cluster of differentiation 98 heavy chain (CD98hc)-specific binding protein, wherein the CD98hc-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to CD98hc with a K<sub>D</sub>of 200 nM or lower.
IPC codes: C07K  16/    28            A I
Claims: number: 1
text: A cluster of differentiation 98 heavy chain (CD98hc)-specific binding protein, wherein the CD98hc-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to CD98hc with a K<D> of 200 nM or lower.
number: 2
text: The CD98hc-specific binding protein of claim 2, wherein the CD98hc-specific binding protein specifically binds to an epitope of CD98hc comprising one or more amino acids from amino acid positions 128 to 137 of SEQ ID NO: 1 and/or one or more amino acids from amino acid positions 374 to 404 of SEQ ID NO: 1.
number: 3
text: The CD98hc-specific binding protein of claim 1 or 2, wherein the CD98hc-specific binding protein
number: 4
text: The CD98hc-specific binding protein of claim 1 or 2, wherein the CD98hc-specific binding protein
number: 5
text: The CD98hc-specific binding protein of claim 1 or 2, wherein the CD98hc-specific binding protein comprises or consists of
number: 6
text: A nucleic acid molecule encoding the CD98hc-specific binding protein of any one of claims 1 to 5.
number: 7
text: A vector comprising the nucleic acid molecule of claim 6.
number: 8
text: A host cell transformed with the vector of claim 7.
number: 9
text: A method for the production of the CD98hc-specific binding protein of any one of claims 1 to 5, the method comprising culturing the host cell of claim 8 under suitable conditions and isolating the CD98hc-specific binding protein produced.
number: 10
text: A protein conjugate or fusion protein comprising the CD98hc-specific binding protein of any one of claims 1 to 5.
number: 11
text: The protein conjugate or fusion protein of claim 10, wherein the CD98hc-specific binding protein is conjugated to or is part of a fusion protein wherein the fusion partner is
number: 12
text: The protein conjugate or fusion protein of claim 10, wherein the CD98hc-specific binding protein is conjugated to a binding protein,
wherein the binding protein is preferably selected from an antibody or immunoglobulin, an antibody fragment and an antibody mimetic,
wherein the antibody mimetic is preferably selected from the group consisting of an Anticalin, Affibody, Adnectin, DARPin, Avimer, Nanofitin, Affilin, β-Wrapin, ADAPT, Monobody, Rasln, FingR, Pronectin, Centyrin, Affimer, Adhiron, Affitin, αRep, Repebody, i-body, Fynomer and a Kunitz domain protein.
number: 13
text: A pharmaceutical composition or a diagnostic composition comprising at least one of
number: 14
text: The CD98hc-specific binding protein of any one of claims 1 to 5, the nucleic acid molecule of claim 6, the vector of claim 7, the host cell of claim 8, or the protein conjugate or fusion protein of any one of claims 10 to 12 for use in therapy and/or diagnosis, preferably for use in treating or diagnosing a disease in the brain and/or the spinal cord.
number: 15
text: The CD98hc-specific binding protein of to any one of claims 1 to 5, the nucleic acid molecule of claim 6, the vector of claim 7, the host cell of claim 8, or the protein conjugate or fusion protein of any one of claims 10 to 12 for use in the therapy and/or diagnosis of a tumor or a neurological disease, wherein the neurological disease is preferably located in the brain and/or the spinal cord.
Office action: search_report, dated 2020-09-30
Rejection reasons: inventive_step_epc_56
Prior art cited: ref_id: WO2008022759A2
ref_type: patent
severity: background
ref_id: - HARLOW; LANE: "Antibodies: A Laboratory Manual", 1988, COLD SPRING HARBOR LABORATORY PRESS
ref_type: npl
severity: background
ref_id: - HARLOW; LANE: "Using Antibodies: A Laboratory Manual", 1999, COLD SPRING HARBOR LABORATORY PRESS
ref_type: npl
severity: background
ref_id: - SCHIEFNER, A.; SKERRA, A., ACC. CHEM. RES., vol. 48, 2015, pages 976 - 985
ref_type: npl
severity: background
ref_id: - "UniProt", Database accession no. P80188
ref_type: npl
severity: background
ref_id: - "UniProt", Database accession no. P08195-2
ref_type: npl
severity: background
ref_id: - DE JONG, L.A.A. ET AL., J. CHROMATOGR. B, vol. 829, no. 1-2, 2005, pages 1 - 25
ref_type: npl
severity: background
ref_id: - HEINRICH, L. ET AL., J. IMMUNOL. METHODS, vol. 352, no. 1-2, 2010, pages 13 - 22
ref_type: npl
severity: background
ref_id: - "Protein-Ligand Interactions, Methods and Applications", 2013, SPRINGER
ref_type: npl
severity: background
ref_id: - ALTSCHUL, S.F. ET AL.: "Nucleic Acids Res.", vol. 25, 1997, pages: 3389 - 3402
ref_type: npl
severity: background
ref_id: - TOMPSON, J.D. ET AL., NUCLEIC ACIDS RES., vol. 22, 1994, pages 4673 - 4680
ref_type: npl
severity: background
ref_id: - PEARSON, W.R.; LIPMAN, D.J., PROC. NATL. ACAD. SCI. U.S.A., vol. 85, 1988, pages 2444 - 2448
ref_type: npl
severity: background
ref_id: - HENIKOFF, S.; HENIKOFF, J.G., PROC. NATL. ACAD. SCI. U.S.A., vol. 89, 1992, pages 10915 - 10919
ref_type: npl
severity: background
ref_id: - BRAASCH, D.A.; COREY, D.R., CHEM. BIOL., vol. 8, 2001, pages 1 - 7
ref_type: npl
severity: background
ref_id: - GEBAUER, M.; SKERRA, A., METH. ENZYMOL., vol. 503, 2012, pages 157 - 188
ref_type: npl
severity: background
ref_id: - OWENS, G.C. ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 98, 2001, pages 1471 - 1476
ref_type: npl
severity: background
ref_id: - SAMBROOK; RUSSEL: "Molecular cloning a laboratory manual", 2001, COLD SPRING HARBOR LABORATORY
ref_type: npl
severity: background
ref_id: - PHAM, P.L. ET AL., MOL. BIOTECHNOL., vol. 34, 2006, pages 225 - 237
ref_type: npl
severity: background
ref_id: - GEISSE, S.; VOEDISCH, B., METHODS MOL. BIOL., vol. 899, 2012, pages 203 - 219
ref_type: npl
severity: background
ref_id: - HACKER, D.L. ET AL., PROTEIN EXPR. PURIF., vol. 92, 2013, pages 67 - 76
ref_type: npl
severity: background
ref_id: - BROWNE, S.M.; AL-RUBEAI, M., TRENDS BIOTECHNOL., vol. 25, 2007, pages 425 - 432
ref_type: npl
severity: background
ref_id: - MATASCI, M ET AL., DRUG DISCOV. TODAY: TECHNOL., vol. 5, 2008, pages e37 - e42
ref_type: npl
severity: background
ref_id: - WURM, F.M., NAT. BIOTECHNOL., vol. 22, 2004, pages 1393 - 1398
ref_type: npl
severity: background
ref_id: - SAMBROOK, J; RUSSEL, D.W.: "Molecular cloning a laboratory manual", 2001, COLD SPRING HARBOR LABORATORY
ref_type: npl
severity: background
ref_id: - HERMANSON, G.T.: "Bioconjugate Techniques", 2013, ACADEMIC PRESS
ref_type: npl
severity: background
ref_id: - NIELSEN, U.B. ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1591, 2002, pages 109 - 118
ref_type: npl
severity: background
ref_id: - BAGSHAWE, K.D., CURR. DRUG TARGETS, vol. 10, 2009, pages 152 - 157
ref_type: npl
severity: background
ref_id: - CHEN, K.-C., BIOCONJUGATE CHEM., vol. 22, 2011, pages 938 - 948
ref_type: npl
severity: background
ref_id: - HARLOW; LANE: "Antibodies, A Laboratory Manual", 1998, COLD SPRING HARBOR LABORATORY PRESS
ref_type: npl
severity: background
ref_id: - ALTSHULER EP; SEREBRYANAYA DV; KATRUKHA AG, BIOCHEMISTRY (MOSC, vol. 75, no. 13, 2010, pages 1584
ref_type: npl
severity: background
ref_id: - HOLLIGER P; HUDSON PJ, NAT BIOTECHNOL., vol. 23, no. 9, 2005, pages 1126
ref_type: npl
severity: background
ref_id: - KONTERMANN; BRINKMANN, DRUG DISCOVERY TODAY, vol. 20, no. 7, 2015, pages 838 - 847
ref_type: npl
severity: background
ref_id: - ALTSHULER, E. ET AL., BIOCHEM. (MOSC., vol. 75, 2010, pages 1584 - 1605
ref_type: npl
severity: background
ref_id: - HOLLIGER, P.; HUDSON, P.J., NAT. BIOTECHNOL., vol. 23, 2005, pages 1126 - 1136
ref_type: npl
severity: background
ref_id: - STROHL W., CURR OPIN BIOTECHNOL, vol. 20, 2009, pages 685 - 691
ref_type: npl
severity: background
ref_id: - JOHNSON G.; WU T.T., NUCLEIC ACIDS RES., vol. 28, 2000, pages 214 - 218
ref_type: npl
severity: background
ref_id: - ROTHE; SKERRA, BIODRUGS, vol. 32, 2018, pages 233 - 243
ref_type: npl
severity: background
ref_id: - FELDWISCH, J; TOLMACHEV, V., METHODS MOL. BIOL., vol. 899, 2012, pages 103 - 126
ref_type: npl
severity: background
ref_id: - GEBAUER, M.; SKERRA, A., CURR. OPIN. CHEM. BIOL., vol. 13, 2009, pages 245 - 255
ref_type: npl
severity: background
ref_id: - WEIDLE UH ET AL., CANCER GENOMICS PROTEOMICS, vol. 10, no. 4, 2013, pages 155 - 68
ref_type: npl
severity: background
ref_id: - MOURATOU B; BEHAR G; PAILLARD-LAURANCE L; COLINET S; PECORARI F., METHODS MOL BIOL., vol. 805, 2012, pages 315 - 31
ref_type: npl
severity: background
ref_id: - KOIDE ET AL., J. MOL. BIOL., vol. 284, 1998, pages 1141 - 51
ref_type: npl
severity: background
ref_id: - ORR ET AL., COMPUTERS & CHEMICAL ENGINEERING, vol. 116, no. 4, 2018, pages 322 - 332
ref_type: npl
severity: background
ref_id: - GAROUSI ET AL., CANCER RES., vol. 75, no. 20, 2015, pages 4364 - 71
ref_type: npl
severity: background
ref_id: - CETIN, J MOL BIOL., vol. 429, no. 4, 2017, pages 562 - 573
ref_type: npl
severity: background
ref_id: - GROSS, NEURON., vol. 78, no. 6, 2013, pages 971 - 985
ref_type: npl
severity: background
ref_id: - DIEM ET AL., PROTEIN ENG., DES. AND SEL., vol. 27, 2014, pages 419 - 429
ref_type: npl
severity: background
ref_id: - TIEDE ET AL., ELIFE., vol. 6, 2017, pages e24903
ref_type: npl
severity: background
ref_id: - TIEDE ET AL., PROTEIN ENG. DES. SEL., vol. 27, 2014, pages 145 - 55
ref_type: npl
severity: background
ref_id: - HADPECH ET AL., SCIENTIFIC REPORTS, vol. 7, 2017
ref_type: npl
severity: background
ref_id: - LEE, PROC NATL ACAD SCI, vol. 109, no. 9, 2012, pages 3299 - 3304
ref_type: npl
severity: background
ref_id: - GRABULOVSKI ET AL., JBC, vol. 282, 2007, pages 3196 - 3204
ref_type: npl
severity: background
ref_id: - BERTSCHINGER ET AL., PROTEIN ENG DES SEL, vol. 20, no. 2, 2007, pages 57 - 68
ref_type: npl
severity: background
ref_id: - GEBAUER; SKERRA, CURR OPINION IN CHEMICAL BIOLOGY, vol. 13, 2009, pages 245 - 255
ref_type: npl
severity: background
ref_id: - SCHLATTER ET AL., MABS, vol. 4, no. 4, 2012, pages 1 - 12
ref_type: npl
severity: background
ref_id: - WEIDLE ET AL., CANCER GENOMICS PROTEOMICS, vol. 10, no. 4, 2013, pages 155 - 68
ref_type: npl
severity: background
ref_id: - ANSARIS ET AL., BRITISH JOURNAL OF CANCERVOLUME, vol. 118, 2018, pages 1115 - 1122
ref_type: npl
severity: background
ref_id: - ZUCHERO ET AL., NEURON, vol. 89, no. 1, 2016, pages 70 - 82
ref_type: npl
severity: background
ref_id: - "UniProt", Database accession no. P10852-1
ref_type: npl
severity: background
ref_id: - CANTOR JM; GINSBERG MH: "CD98 at the crossroads of adaptive immunity and cancer", JOURNAL OF CELL SCIENCE, vol. 125, 2012, pages 1373 - 82
ref_type: npl
severity: background
ref_id: - FOTIADIS D; KANAI Y; PALACIN M, THE SLC3 AND SLC7 FAMILIES OF AMINO ACID TRANSPORTERS MOLECULAR ASPECTS OF MEDICINE, vol. 34, 2013, pages 139 - 58
ref_type: npl
severity: background
ref_id: - KANAI Y; SEGAWA H; MIYAMOTO K; UCHINO H; TAKEDA E; ENDOU H: "Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, 1998, pages 23629 - 32, XP002925590, DOI: doi:10.1074/jbc.273.37.23629
ref_type: npl
severity: background
ref_id: - PINEDA M; FERNANDEZ E; TORRENTS D; ESTEVEZ R; LOPEZ C; CAMPS M ET AL.: "Identification of a membrane protein, LAT-2, that Co-expresses with 4F2 heavy chain, an L-type amino acid transport activity with broad specificity for small and large zwitterionic amino acids", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 19738 - 44
ref_type: npl
severity: background
ref_id: - TORRENTS D; ESTEVEZ R; PINEDA M; FERNANDEZ E; LLOBERAS J; SHI YB ET AL.: "Identification and characterization of a membrane protein (y+L amino acid transporter-1) that associates with 4F2hc to encode the amino acid transport activity y+L. A candidate gene for lysinuric protein intolerance", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 273, 1998, pages 32437 - 45, XP002178117, DOI: doi:10.1074/jbc.273.49.32437
ref_type: npl
severity: background
ref_id: - BROER A; WAGNER CA; LANG F; BROER S: "The heterodimeric amino acid transporter 4F2hc/y+LAT2 mediates arginine efflux in exchange with glutamine", THE BIOCHEMICAL JOURNAL, vol. 3, 2000, pages 787 - 95, XP002381266
ref_type: npl
severity: background
ref_id: - FUKASAWA Y; SEGAWA H; KIM JY; CHAIROUNGDUA A; KIM DK; MATSUO H ET AL.: "Identification and characterization of a Na(+)-independent neutral amino acid transporter that associates with the 4F2 heavy chain and exhibits substrate selectivity for small neutral D- and L-amino acids", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, 2000, pages 9690 - 8, XP002235447, DOI: doi:10.1074/jbc.275.13.9690
ref_type: npl
severity: background
ref_id: - SATO H; TAMBA M; ISHII T; BANNAI S: "Cloning and expression of a plasma membrane cystine/glutamate exchange transporter composed of two distinct proteins", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 11455 - 8, XP002941607, DOI: doi:10.1074/jbc.274.17.11455
ref_type: npl
severity: background
ref_id: - NAKAMURA E; SATO M; YANG H; MIYAGAWA F; HARASAKI M; TOMITA K ET AL.: "4F2 (CD98) heavy chain is associated covalently with an amino acid transporter and controls intracellular trafficking and membrane topology of 4F2 heterodimer", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, 1999, pages 3009 - 16
ref_type: npl
severity: background
ref_id: - NICKLIN P; BERGMAN P; ZHANG B; TRIANTAFELLOW E; WANG H; NYFELER B ET AL.: "Bidirectional transport of amino acids regulates mTOR and autophagy", CELL, vol. 136, 2009, pages 521 - 34
ref_type: npl
severity: background
ref_id: - KOPPULA P; ZHANG Y; ZHUANG L; GAN B.: "Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer", CANCER COMMUNICATIONS, vol. 38, 2018, pages 12
ref_type: npl
severity: background
ref_id: - YOSHIDA GJ: "Metabolic reprogramming: The emerging concept and associated therapeutic strategies", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 34, 2015, pages 111, XP021229409, DOI: doi:10.1186/s13046-015-0221-y
ref_type: npl
severity: background
ref_id: - CANTOR JM; GINSBERG MH; ROSE DM: "Integrin-associated proteins as potential therapeutic targets", IMMUNOLOGICAL REVIEWS, vol. 223, 2008, pages 236 - 51
ref_type: npl
severity: background
ref_id: - MIYAMOTO YJ; MITCHELL JS; MCLNTYRE BW: "Physical association and functional interaction between β1 integrin and CD98 on human T lymphocytes", MOLECULAR IMMUNOLOGY, vol. 39, 2003, pages 739 - 51
ref_type: npl
severity: background
ref_id: - ZENT R; FENCZIK CA; CALDERWOOD DA; LIU S; DELLOS M; GINSBERG MH: "Class- and splice variant-specific association of CD98 with integrin β cytoplasmic domains", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 275, 2000, pages 5059 - 64
ref_type: npl
severity: background
ref_id: - HENDERSON NC; COLLIS EA; MACKINNON AC; SIMPSON KJ; HASLETT C; ZENT R ET AL.: "CD98hc (SLC3A2) interaction with β1 integrins is required for transformation", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 279, 2004, pages 54731 - 41, XP002667313, DOI: doi:10.1074/JBC.M408700200
ref_type: npl
severity: background
ref_id: - BAJAJ J; KONUMA T; LYTLE NK; KWON HY; ABLACK JN; CANTOR JM ET AL.: "CD98-mediated adhesive signaling enables the establishment and propagation of acute myelogenous leukemia", CANCER CELL, vol. 30, 2016, pages 792 - 805, XP029813183, DOI: doi:10.1016/j.ccell.2016.10.003
ref_type: npl
severity: background
ref_id: - YE Y; WANG M; WANG B; YANG X-M; CHEN Z-N: "CD98, a potential diagnostic cancer-related biomarker, and its prognostic impact in colorectal cancer patients", INT J CLIN EXP PATHOL., vol. 10, 2017, pages 5418 - 29
ref_type: npl
severity: background
ref_id: - KAIRA K; ORIUCHI N; IMAI H; SHIMIZU K; YANAGITANI N; SUNAGA N ET AL.: "CD98 expression is associated with poor prognosis in resected non-small-cell lung cancer with lymph node metastases", ANN SURG ONCOL., vol. 16, 2009, pages 3473 - 81, XP019745464, DOI: doi:10.1245/s10434-009-0685-0
ref_type: npl
severity: background
ref_id: - HAYES GM; CHINN L; CANTOR JM; CAIRNS B; LEVASHOVA Z; TRAN H ET AL.: "Antitumor activity of an anti-CD98 antibody", INTERNATIONAL JOURNAL OF CANCER, vol. 137, 2015, pages 710 - 20, XP055403713, DOI: doi:10.1002/ijc.29415
ref_type: npl
severity: background
ref_id: - EL ANSARI R; CRAZE ML; DIEZ-RODRIGUEZ M; NOLAN CC; ELLIS 10; RAKHA EA ET AL.: "The multifunctional solute carrier 3A2 (SLC3A2) confers a poor prognosis in the highly proliferative breast cancer subtypes", BRIT J CANCER, vol. 118, 2018, pages 1115 - 22, XP036740994, DOI: doi:10.1038/s41416-018-0038-5
ref_type: npl
severity: background
ref_id: - FURUYA M; HORIGUCHI J; NAKAJIMA H; KANAI Y; OYAMA T: "Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis", CANCER SCI., vol. 103, 2012, pages 382 - 9
ref_type: npl
severity: background
ref_id: - WANG Q; TIFFEN J; BAILEY CG; LEHMAN ML; RITCHIE W; FAZLI L ET AL.: "Targeting amino acid transport in metastatic castration-resistant prostate cancer: Effects on cell cycle, cell growth, and tumor development", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 105, 2013, pages 1463 - 73
ref_type: npl
severity: background
ref_id: - SALTER DM; KRAJEWSKI AS; SHEEHAN T; TURNER G; CUTHBERT RJ; MCLEAN A: "Prognostic significance of activation and differentiation antigen expression in B-cell non-Hodgkin's lymphoma", THE JOURNAL OF PATHOLOGY, vol. 159, 1989, pages 211 - 20
ref_type: npl
severity: background
ref_id: - DIGOMANN D; KURTH I; TYUTYUNNYKOVA A; CHEN O; LOCK S; GORODETSKA I ET AL.: "The CD98 heavy chain is a marker and regulator of head and neck squamous cell carcinoma radiosensitivity", CLINICAL CANCER RESEARCH : AN OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 2019
ref_type: npl
severity: background
ref_id: - YANG H; ZOU W; LI Y; CHEN B; XIN X: "Bridge linkage role played by CD98hc of anti-tumor drug resistance and cancer metastasis on cisplatin-resistant ovarian cancer cells", CANCER BIOLOGY & THERAPY, vol. 6, 2007, pages 942 - 7
ref_type: npl
severity: background
ref_id: - KAIRA K; OHDE Y; ENDO M; NAKAGAWA K; OKUMURA T; TAKAHASHI T ET AL.: "Expression of 4F2hc (CD98) in pulmonary neuroendocrine tumors", ONCOLOGY REPORTS, vol. 26, 2011, pages 931 - 7
ref_type: npl
severity: background
ref_id: - RIETBERGEN MM; MARTENS-DE KEMP SR; BLOEMENA E; WITTE BI; BRINK A; BAATENBURG DE JONG RJ ET AL.: "Cancer stem cell enrichment marker CD98: A prognostic factor for survival in patients with human papillomavirus-positive oropharyngeal cancer", EUROPEAN JOURNAL OF CANCER, vol. 50, 1990, pages 765 - 73
ref_type: npl
severity: background
ref_id: - PRAGER GW; POETTLER M; SCHMIDINGER M; MAZAL PR; SUSANI M; ZIELINSKI CC ET AL.: "CD98hc (SLC3A2), a novel marker in renal cell cancer", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 39, 2009, pages 304 - 10
ref_type: npl
severity: background
ref_id: - ISODA A; KAIRA K; IWASHINA M; ORIUCHI N; TOMINAGA H; NAGAMORI S ET AL.: "Expression of L-type amino acid transporter 1 (LAT1) as a prognostic and therapeutic indicator in multiple myeloma", CANCER SCI., vol. 105, 2014, pages 1496 - 502
ref_type: npl
severity: background
ref_id: - KAIRA K; ORIUCHI N; IMAI H; SHIMIZU K; YANAGITANI N; SUNAGA N ET AL.: "L-type amino acid transporter 1 and CD98 expression in primary and metastatic sites of human neoplasms", CANCER SCI., vol. 99, 2008, pages 2380 - 6, XP055073515, DOI: doi:10.1111/j.1349-7006.2008.00969.x
ref_type: npl
severity: background
ref_id: - TOYODA M; KAIRA K; SHINO M; SAKAKURA K; TAKAHASHI K; TAKAYASU Y ET AL.: "CD98 as a novel prognostic indicator for patients with stage III/IV hypopharyngeal squamous cell carcinoma", HEAD & NECK., vol. 37, 2015, pages 1569 - 74
ref_type: npl
severity: background
ref_id: - HAYASHI K; ANZAI N: "Novel therapeutic approaches targeting L-type amino acid transporters for cancer treatment", WORLD J GASTROINTEST ONCOL., vol. 9, 2017, pages 21 - 9
ref_type: npl
severity: background
ref_id: - SALISBURY TB; ARTHUR S: "The regulation and function of the L-type amino acid transporter 1 (LAT1) in cancer", INT J MOL SCI., vol. 19, 2018, pages 2373
ref_type: npl
severity: background
ref_id: - BAROLLO S; BERTAZZA L; WATUTANTRIGE-FERNANDO S; CENSI S; CAVEDON E; GALUPPINI F ET AL.: "Overexpression of L-type amino acid transporter 1 (LAT1) and 2 (LAT2): Novel markers of neuroendocrine tumors", PLOS ONE, vol. 11, 2016
ref_type: npl
severity: background
ref_id: - SUGANO K; MAEDA K; OHTANI H; NAGAHARA H; SHIBUTANI M; HIRAKAWA K: "Expression of xCT as a predictor of disease recurrence in patients with colorectal cancer", ANTICANCER RES., vol. 35, 2015, pages 677 - 82
ref_type: npl
severity: background
ref_id: - JI X; QIAN J; RAHMAN SMJ; SISKA PJ; ZOU Y; HARRIS BK ET AL., XCT (SLC7A11)-MEDIATED METABOLIC REPROGRAMMING PROMOTES NON-SMALL CELL LUNG CANCER PROGRESSION ONCOGENE, vol. 37, 2018, pages 5007 - 19
ref_type: npl
severity: background
ref_id: - KAIRA K; ORIUCHI N; IMAI H; SHIMIZU K; YANAGITANI N; SUNAGA N ET AL.: "Prognostic significance of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in early stage squamous cell carcinoma of the lung", CANCER SCI., vol. 100, 2009, pages 249 - 54
ref_type: npl
severity: background
ref_id: - NAKANISHI K; OGATA S; MATSUO H; KANAI Y; ENDOU H; HIROI S ET AL.: "Expression of LAT1 predicts risk of progression of transitional cell carcinoma of the upper urinary tract", VIRCHOWS ARCH A., vol. 451, 2007, pages 681 - 90, XP019542451, DOI: doi:10.1007/s00428-007-0457-9
ref_type: npl
severity: background
ref_id: - BIXBY D; WIEDUWILT MJ; AKARD LP; KHOURY HJ; BECKER PS; VAN DER HORST EH ET AL.: "A Phase I Study of IGN523, a Novel Anti-CD98 Monoclonal Antibody in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML", BLOOD, vol. 126, 2015, pages 3809
ref_type: npl
severity: background
ref_id: - WANG Q; HOIST J.: "L-type amino acid transport and cancer: Targeting the mTORC1 pathway to inhibit neoplasia", AM J CANCER RES., vol. 5, 2015, pages 1281 - 94
ref_type: npl
severity: background
ref_id: - KLASNER BD; KRAUSE BJ; BEER AJ; DRZEZGA A: "PET imaging of gliomas using novel tracers: A sleeping beauty waiting to be kissed", EXPERT REVIEW OF ANTICANCER THERAPY, vol. 10, 2010, pages 609 - 13
ref_type: npl
severity: background
ref_id: - IKOTUN OF; MARQUEZ BV; HUANG C; MASUKO K; DAIJI M; MASUKO T ET AL.: "Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET", PLOS ONE, vol. 8, 2013
ref_type: npl
severity: background
ref_id: - HUTTERER M; NOWOSIELSKI M; PUTZER D; JANSEN NL; SEIZ M; SCHOCKE M ET AL.: "18F]-fluoro-ethyl-L-tyrosine PET: A valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma", NEURO-ONCOLOGY, vol. 15, 2013, pages 341 - 51
ref_type: npl
severity: background
ref_id: - SINGH N; ECKER GF: "Insights into the structure, function, and ligand discovery of the large neutral amino acid transporter 1", LAT1. INT J MOL SCI., 2018, pages 19
ref_type: npl
severity: background
ref_id: - MENDLER CT; FRIEDRICH L; LAITINEN I; SCHLAPSCHY M; SCHWAIGER M; WESTER HJ ET AL.: "High contrast tumor imaging with radio-labeled antibody Fab fragments tailored for optimized pharmacokinetics via PASylation", MABS, vol. 7, 2015, pages 96 - 109, XP055274067, DOI: doi:10.4161/19420862.2014.985522
ref_type: npl
severity: background
ref_id: - RICHTER A; EGGENSTEIN E; SKERRA A: "Anticalins: Exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins", FEBS LETTERS, vol. 588, 2014, pages 213 - 8, XP028669980, DOI: doi:10.1016/j.febslet.2013.11.006
ref_type: npl
severity: background
ref_id: - ROTHE C; SKERRA A: "Anticalin® proteins as therapeutic agents in human diseases", BIODRUGS, vol. 32, 2018, pages 233 - 43
ref_type: npl
severity: background
ref_id: - SCHLAPSCHY M; BINDER U; BORGER C; THEOBALD I; WACHINGER K; KISLING S ET AL.: "PASylation: A biological alternative to PEGylation for extending the plasma half-life of pharmaceutically active proteins", PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS, vol. 26, 2013, pages 489 - 501, XP055195431, DOI: doi:10.1093/protein/gzt023
ref_type: npl
severity: background
ref_id: - GEBAUER M; SCHIEFNER A; MATSCHINER G; SKERRA A: "Combinatorial design of an Anticalin directed against the extra-domain b for the specific targeting of oncofetal fibronectin", JOURNAL OF MOLECULAR BIOLOGY, vol. 425, 2013, pages 780 - 802, XP028970028, DOI: doi:10.1016/j.jmb.2012.12.004
ref_type: npl
severity: background
ref_id: - FRIEDRICH L; KORNBERGER P; MENDLER CT; MULTHOFF G; SCHWAIGER M; SKERRA A: "Selection of an Anticalin® against the membrane form of Hsp70 via bacterial surface display and its theranostic application in tumour models", BIOLOGICAL CHEMISTRY, vol. 399, 2018, pages 235 - 52
ref_type: npl
severity: background
ref_id: - MUELLER U; DAROWSKI N; FUCHS MR; FORSTER R; HELLMIG M; PAITHANKAR KS ET AL.: "Facilities for macromolecular crystallography at the Helmholtz-Zentrum Berlin", J SYNCHROTRON RADIAT., vol. 19, 2012, pages 442 - 9
ref_type: npl
severity: background
ref_id: - KABSCH W. XDS., ACTA CRYSTALLOGRAPHICA SECTION D BIOLOGICAL CRYSTALLOGRAPHY, vol. 66, 2010, pages 125 - 32
ref_type: npl
severity: background
ref_id: - MCCOY AJ; GROSSE-KUNSTLEVE RW; ADAMS PD; WINN MD; STORONI LC; READ RJ: "Phaser crystallographic software", J APPL CRYSTALLOGR., vol. 40, 2007, pages 658 - 74
ref_type: npl
severity: background
ref_id: - FORT J; DE LA BALLINA LR; BURGHARDT HE; FERRER-COSTA C; TURNAY J; FERRER-ORTA C ET AL.: "The structure of human 4F2hc ectodomain provides a model for homodimerization and electrostatic interaction with plasma membrane", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 282, 2007, pages 31444 - 52, XP055054290, DOI: doi:10.1074/jbc.M704524200
ref_type: npl
severity: background
ref_id: - EMSLEY P; LOHKAMP B; SCOTT WG; COWTAN K: "Features and development of Coot", ACTA CRYSTALLOGRAPHICA SECTION D BIOLOGICAL CRYSTALLOGRAPHY, vol. 66, 2010, pages 486 - 501
ref_type: npl
severity: background
ref_id: - MURSHUDOV GN; SKUBAK P; LEBEDEV AA; PANNU NS; STEINER RA; NICHOLLS RA ET AL.: "REFMAC5 for the refinement of macromolecular crystal structures", ACTA CRYSTALLOGRAPHICA SECTION D BIOLOGICAL CRYSTALLOGRAPHY, vol. 67, 2011, pages 355 - 67
ref_type: npl
severity: background
ref_id: - PAINTER J; MERRITT EA: "TLSMD web server for the generation of multi-group TLS models", J APPL CRYSTALLOGR., vol. 39, 2006, pages 109 - 11
ref_type: npl
severity: background
ref_id: - BARKOVSKIY M; LLYUKHINA E; DAUNER M; EICHINGER A; SKERRA A: "An engineered lipocalin that tightly complexes the plant poison colchicine for use as antidote as well as bioanalytical applications", BIOLOGICAL CHEMISTRY, 2018
ref_type: npl
severity: background
ref_id: - BINDER U; MATSCHINER G; THEOBALD I; SKERRA A: "High-throughput sorting of an Anticalin library via EspP-mediated functional display on the Escherichia coli cell surface", JOURNAL OF MOLECULAR BIOLOGY, vol. 400, 2010, pages 783 - 802, XP027244152, DOI: doi:10.1016/j.jmb.2010.05.049
ref_type: npl
severity: background
ref_id: - COSTA J; GRABENHORST E; NIMTZ M; CONRADT HS: "Stable expression of the Golgi form and secretory variants of human fucosyltransferase III from BHK-21 cells", THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 272, 1997, pages 11613 - 21, XP002183458, DOI: doi:10.1074/jbc.272.17.11613
ref_type: npl
severity: background
ref_id: - SCHLEHUBER S; SKERRA A: "Tuning ligand affinity, specificity, and folding stability of an engineered lipocalin variant — a so-called 'anticalin' — using a molecular random approach", BIOPHYS CHEM., vol. 96, 2002, pages 213 - 28, XP002265035, DOI: doi:10.1016/S0301-4622(02)00026-1
ref_type: npl
severity: background
ref_id: - VOSJAN MJ; PERK LR; VISSER GW; BUDDE M; JUREK P; KIEFER GE ET AL.: "Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine", NAT PROTOC., vol. 5, 2010, pages 739 - 43, XP055304936, DOI: doi:10.1038/nprot.2010.13
ref_type: npl
severity: background
ref_id: - WOLLSCHEID B; BAUSCH-FLUCK D; HENDERSON C; O'BRIEN R; BIBEL M; SCHIESS R ET AL.: "Mass-spectrometric identification and relative quantification of N-linked cell surface glycoproteins", NATURE BIOTECHNOLOGY, vol. 27, 2009, pages 378 - 86
ref_type: npl
severity: background
ref_id: - BARINKA C; PTACEK J; RICHTER A; NOVAKOVA Z; MORATH V; SKERRA A, SELECTION AND CHARACTERIZATION OF ANTICALINS TARGETING HUMAN PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) PROTEIN ENGINEERING, DESIGN & SELECTION : PEDS., vol. 29, 2016, pages 105 - 15
ref_type: npl
severity: background
ref_id: - BECKETT D; KOVALEVA E; SCHATZ PJ, A MINIMAL PEPTIDE SUBSTRATE IN BIOTIN HOLOENZYME SYNTHETASE-CATALYZED BIOTINYLATION PROTEIN SCIENCE : A PUBLICATION OF THE PROTEIN SOCIETY, vol. 8, 1999, pages 921 - 9
ref_type: npl
severity: background
ref_id: - SCHIEFNER A; GEBAUER M; RICHTER A; SKERRA A: "Anticalins reveal high plasticity in the mode of complex formation with a common tumor antigen", STRUCTURE, vol. 26, 1993, pages 649 - 56
ref_type: npl
severity: background
ref_id: - LIPPINCOTT J; VAN DER HORST ETH; ZACHWIEJA J; TRAN H: "Anti-CD98 antibodies and methods of use therof", ORGANIZATION WIP, 2013
ref_type: npl
severity: background
ref_id: - MATTHEWS BW; NICHOLSON H; BECKTEL WJ: "Enhanced protein thermostability from site-directed mutations that decrease the entropy of unfolding", PROC NATL ACAD SCI USA., vol. 84, 1987, pages 6663 - 7
ref_type: npl
severity: background
ref_id: - BINDER U; SKERRA A: "PASy|ation| : A versatile technology to extend drug delivery", CURR OPIN COLLOID INTERFACE SCI, vol. 31, 2017, pages 10 - 7, XP085232208, DOI: doi:10.1016/j.cocis.2017.06.004
ref_type: npl
severity: background
ref_id: - PAPETTI M; HERMAN IM: "Controlling tumor-derived and vascular endothelial cell growth: Role of the 4Ff2 cell surface antigen", AM J PATHOL., vol. 159, 2001, pages 165 - 78, XP009167297, DOI: doi:10.1016/S0002-9440(10)61683-5
ref_type: npl
severity: background
ref_id: - FISCHER G; SEIBOLD U; SCHIRRMACHER R; WANGLER B; WANGLER C: "89)Zr, a radiometal nuclide with high potential for molecular imaging with PET: Chemistry, applications and remaining challenges", MOLECULES (BASEL, SWITZERLAND, vol. 18, 2013, pages 6469 - 90, XP055147850, DOI: doi:10.3390/molecules18066469
ref_type: npl
severity: background
ref_id: - ABOU DS; KU T; SMITH-JONES PM: "In vivo biodistribution and accumulation of 89Zr in mice", NUCLEAR MEDICINE AND BIOLOGY, vol. 38, 2011, pages 675 - 81, XP028234569, DOI: doi:10.1016/j.nucmedbio.2010.12.011
ref_type: npl
severity: background
ref_id: - RICHTER A; SKERRA A: "Anticalins directed against vascular endothelial growth factor receptor 3 (VEGFR-3) with picomolar affinities show potential for medical therapy and in vivo imaging", BIOLOGICAL CHEMISTRY, vol. 398, 2017, pages 39 - 55
ref_type: npl
severity: background
ref_id: - RAUTH S; HINZ D; BORGER M; UHRIG M; MAYHAUS M; RIEMENSCHNEIDER M ET AL.: "High-affinity Anticalins with aggregation-blocking activity directed against the Alzheimer beta-amyloid peptide", THE BIOCHEMICAL JOURNAL, vol. 473, 2016, pages 1563 - 78, XP009191367, DOI: doi:10.1042/BCJ20160114
ref_type: npl
severity: background
ref_id: - MENDLER CT; GEHRING T; WESTER HJ; SCHWAIGER M; SKERRA A: "89)Zr-labeled versus (124)1-labeled aHER2 Fab with optimized plasma half-life for high-contrast tumor imaging in vivo. Journal of nuclear medicine : official publication", SOCIETY OF NUCLEAR MEDICINE, vol. 56, 2015, pages 1112 - 8
ref_type: npl
severity: background
ref_id: - SUMMER D; GAROUSI J; OROUJENI M; MITRAN B; ANDERSSON KG; VOROBYEVA A ET AL.: "Cyclic versus noncyclic chelating scaffold for (89)Zr-labeled ZEGFR:2377 Affibody bioconjugates targeting epidermal growth factor receptor overexpression", MOLECULAR PHARMACEUTICS, vol. 15, 2018, pages 175 - 85
ref_type: npl
severity: background
ref_id: - SUMMER D; RANGGER C; KLINGLER M; LAVERMAN P; FRANSSEN GM; LECHNER BE ET AL.: "Exploiting the concept of multivalency with (68)Ga- and (89)Zr-labeled Fusarinine C-Minigastrin Bioconjugates for targeting CCK2R expression", CONTRAST MEDIA & MOLECULAR IMAGING, 2018, pages 3171794
ref_type: npl
severity: background
ref_id: WO2013078377A1
ref_type: patent
severity: background
ref_id: EP2510357B1
ref_type: patent
severity: background
ref_id: - RICHTER A ET AL: "Anticalins: Exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, vol. 588, no. 2, 12 November 2013 (2013-11-12), pages 213 - 218, XP028669980, ISSN: 0014-5793, DOI: 10.1016/J.FEBSLET.2013.11.006
ref_type: npl
severity: background
ref_id: WO2013078377
ref_type: patent
severity: obviousness
ref_id: EP2510357
ref_type: patent
severity: obviousness
ref_id: - RICHTER A ET AL, "Anticalins: Exploiting a non-Ig scaffold with hypervariable loops for the engineering of binding proteins", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (20131112), vol. 588, no. 2, doi:10.1016/J.FEBSLET.2013.11.006, ISSN 0014-5793, pages 213 - 218, XP028669980 [YD] 1-15 * the whole document *
ref_type: npl
severity: obviousness
Final disposition: pending (2020-09-30)